Allograft failure in kidney transplant recipients who developed kidney failure secondary to ANCA‐associated vasculitis

2021 ◽  
Author(s):  
Lukas Kuhnel ◽  
Carmel M. Hawley ◽  
David W. Johnson ◽  
Glenda C. Gobe ◽  
Robert J. Ellis ◽  
...  
2020 ◽  
Vol 7 ◽  
pp. 205435812092262 ◽  
Author(s):  
Navdeep Tangri ◽  
Thomas W. Ferguson ◽  
Chris Wiebe ◽  
Frederick Eng ◽  
Michelle Nash ◽  
...  

Background: Predicting allograft failure in kidney transplant recipients can help plan renal replacement therapy and guide patient-provider communication. The kidney failure risk equation (KFRE) accurately predicts the need for dialysis in patients with chronic kidney disease (CKD), but has not been validated in kidney transplant recipients. Objective: We sought to validate the 4-variable KFRE (age, sex, estimated glomerular filtration rate [eGFR], and urine albumin-to-creatinine ratio [ACR]) for prediction of 2- and 5-year death-censored allograft failure. Design: Retrospective cohort study. Setting: Four independent North American Cohorts from Ontario, Canada; Alberta, Canada; Manitoba, Canada; and Wisconsin, United States, between January 1999 and December 2017. Patients: Adult kidney transplant patients at 1-year posttransplantation. Measurements: Kidney failure risk as measured by the KFRE (eGFR, urine ACR, age, and sex). Methods: We included all adult patients who had at least 1 serum creatinine and at least 1 urine ACR measurement approximately 1 year following kidney transplantation. The performance of the KFRE was evaluated using the area under the receiver operating characteristic curve (C-statistic). C-statistics from the 4 cohorts were meta-analyzed using random-effects models. Results: A total of 3659 patients were included. Pooled C-statistics were good in the entire population, at 0.81 (95% confidence interval: 0.72-0.91) for the 2-year KFRE and 0.73 (0.67-0.80) for the 5-year KFRE. Discrimination improved among patients with poorer kidney function (eGFR < 45 mL/min/1.73 m2), with a C-statistic of 0.88 (0.78-0.98) for the 2-year KFRE and 0.83 (0.74-0.91) for the 5-year KFRE. Limitations: The KFRE does not predict episodes of acute rejection and there was heterogeneity between cohorts. Conclusions: The KFRE accurately predicts kidney failure in kidney transplant recipients at 1-year posttransplantation. Further validation in larger cohorts with longer follow-up times can strengthen the case for clinical implementation.


2020 ◽  
Vol 20 (10) ◽  
pp. 2822-2831 ◽  
Author(s):  
Sandesh Parajuli ◽  
Brenda L. Muth ◽  
Brad C. Astor ◽  
Robert R. Redfield ◽  
Didier A. Mandelbrot ◽  
...  

Kidney360 ◽  
2021 ◽  
pp. 10.34067/KID.0003512021
Author(s):  
Thilo Kolb ◽  
Svenja Fischer ◽  
Lisa Müller ◽  
Nadine Lübke ◽  
Jonas Hillebrandt ◽  
...  

Background: Kidney failure patients on dialysis or after renal transplantation have a high risk for severe COVID-19 infection and vaccination against SARS-CoV-2 is the only expedient prophylaxis. Generally, immune responses are attenuated in kidney failure patients, however, systematic analyses of immune responses to SARS-CoV-2 vaccination in dialysis patients and in kidney transplant recipients (KTR) are still missing. Methods: In this prospective multicentric cohort study, antibody responses COVID-19 mRNA vaccines (BNT162b2; Biontech/Pfizer or mRNA-1273; Moderna) were measured in 32 dialysis patients and in 28 KTRs. SARS-CoV-2-specific antibodies and neutralization capacity were evaluated and compared to controls (n=78) in a similar age-range. Results: After the first vaccination, SARS-CoV-2-specific antibodies were nearly undetectable in kidney failure patients. After the second vaccination, 93% of the controls and 88% of dialysis patients but only 37% of KTRs developed SARS-CoV-2-specific IgG above cut-off. Moreover, mean IgG levels were significantly lower in KTRs (54±93 BAU/ml) compared to dialysis patients (503±481 BAU/ml, p<0.01). Both KTRs as well as dialysis patients had significantly lower IgG levels compared to controls (1992±2485 BAU/ml; p<0.001 and p<0.01). Importantly, compared to controls, neutralizing antibody titers were significantly lower in KTRs and dialysis patients. After the second vaccination, 76% of KTRs did not show any neutralization capacity against SARS-CoV-2 suggesting impaired seroprotection. Conclusions: Kidney failure patients show a significantly weaker antibody response compared to controls. Most strikingly, only one out four KTRs developed neutralizing antibodies against SARS-CoV-2 after two doses of vaccine. These data suggest that vaccination strategies need modification in immune transplant and dialysis patients.


2017 ◽  
Vol 69 (3) ◽  
pp. 410-419 ◽  
Author(s):  
Joachim H. Ix ◽  
Ronit Katz ◽  
Nisha Bansal ◽  
Meredith Foster ◽  
Daniel E. Weiner ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document